Answers are grounded in this paper and cite their sources.
There is clear evidence that human ageing is associated with reduced activity of the growth hormone (GH)/insulin-growth factor-I (IGF-I) axis, the so called "somatopause". Although this condition is likely to contribute to age-related changes in body composition, structure functions and metabolism, we are now in face of the paradox of lifelong GH/IGF-I deficiency or resistance resulting in prolonged life expectancy. This evidence questions whether GH deficiency is or is not a beneficial adaptation to ageing. On the other hand, neuroendocrine studies provided evidence that brain ageing is associated to peculiar age-related alterations in the control of GH/IGF-I axis, mostly including GHRH deficiency and SS hyperactivity, reflecting the age-related cholinergic impairment. This hormonal pattern is present in normal and demented elderly subjects, and a neuroendocrine distinction among these conditions is impossible. This review will focus on the age-related decline in the activity of GH/IGF-I axis as a function of either normal or pathological brain ageing. Particularly, the influence of GH/IGF-I axis on cognitive functions and related disorders will be discussed.
No takes yet. Share an insight, caveat, or question.
R. Giordano (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: